US FDA Accepts Aridol New Drug Application for Review

14th May 09

Release Date: 14/05/2009 12:00am

Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced it had received notification from the United States Food and Drug Administration (FDA) that the New Drug Application (NDA) for its mannitol bronchial challenge test Aridol™ has been accepted for standard review. The FDA will advise the result of the review on 27 December 2009.

View PDF